Skip to main content

Table 1 Baseline patient characteristics in three cohorts of metastatic prostate cancer

From: Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer

Baseline Characteristic mCRPC
pre-ARSI (n = 10)
mCRPC
post-ARSI (n = 10)
mHSPC
starting ADT (n = 10)
Total (n = 30)
Age
Median (range) 74 (51–83) 72 (53–88) 72 (55–82) 72 (51–88)
Race
White 9 (90%) 9 (90%) 8 (80%) 26 (87%)
Black or African American 0 (0%) 0 (0%) 2 (20%) 2 (7%)
Other 1 (10%) 1 (10%) 0 (0%) 2 (6%)
PSA (ng/mL)
Median (range) 7 (2–1327) 27 (5–126) 90 (4.3–1427) 32 (2–1427)
Hemoglobin (g/dL)
Median (range) 12.2 (7.9–14.3) 12.2 (9.4–14.1) 13.6 (8.5–16.2) 12.6 (7.9–16.2)
  < 13.7 g/dL (LLN) 9 (90%) 8 (80%) 5 (50%) 22 (73%)
LDH (U/L)
Median (range) 238 (142–517) 224 (117–330) 193 (142–230) 224 (117–517)
  > 100 U/L (ULN) 3 (30%) 7 (70%) 4 (40%) 14 (47%)
Alkaline phosphatase (U/L)
Median (range) 83 (44–877) 87 (41–207) 111 (43–1378) 96 (41–1378)
  > 110 U/L (ULN) 4 (40%) 3 (30%) 5 (50%) 12 (40%)
Prior Chemotherapy
Cabazitaxel 0 (0%) 2 (20%) 0 (0%) 2 (7%)
Docetaxel 3 (30%) 5 (50%) 0 (0%) 8 (27%)
Metastatic Site
  Bone 8 (80%) 10 (100%) 9 (90%) 27 (90%)
  Lymph Nodes (Inside Pelvis) 5 (50%) 3 (30%) 7 (70%) 15 (50%)
  Lymph Node (Outside Pelvis) 4 (40%) 4 (40%) 4 (40%) 12 (40%)
  Liver 0 (0%) 1 (10%) 0 (0%) 1 (3%)
  Lung 2 (20%) 1 (10%) 0 (0%) 3 (10%)
Gleason Grade, Score (sum)
  < 6 1 (10%) 1 (10%) 1 (10%) 3 (10%)
7 3 (30%) 3 (30%) 1 (10%) 7 (23%)
8–10 5 (50%) 6 (10%) 6 (60%) 17 (57%)
Missing 1 (10%) 0 (0%) 2 (20%) 3 (10%)